Cost Per Case, Virus by Virus

The Virus Risk Perspective puts fifteen viruses on the same five-stage funnel so that a measles number and a dengue number are the same kind of number. This is its economic companion: what one case of each virus costs, in the three senses that word has — to a hospital, to society, and to the economy — with every figure traced to a primary source and every division shown. No agency publishes this table. It is assembled from the ones that publish its inputs.

Last reviewed: September 2026 · By Andy Wilcox, independent researcher

Three kinds of number, never added together. A medical cost is what a hospital or health system spends on one patient. A societal cost per illness already contains that plus lost work, caregiving and premature death. An economy-wide loss is output that never happened — closed borders, empty restaurants, workers who stayed home — and most of it lands on people who were never infected. Each column below answers "what does a case cost?" in one of those senses, and the answers differ by a factor of a thousand for the same virus.

The Table

Seven viruses have a per-case figure that meets this network's sourcing rule — CDC, WHO or NIH directly; other official statistics bodies; or peer-reviewed literature cited by DOI. Eight of the fifteen on the Risk Perspective do not yet, and are listed afterwards rather than filled in with something weaker. Where a cell is our division, the inputs are in the derivation column and the sources are numbered to the list at the foot of the page.

Dollar figures are in the value-years their sources state (shown in brackets); they are not inflation-adjusted except where the row says so, because mixing a 2003 West Nile cost with a 2024 norovirus cost is already the reader's problem and a false common year would hide it. "—" means no figure of that kind meets the sourcing rule; it never means zero. Sources are numbered to the reference list. Read September 20, 2026.
Virus Medical cost — one patient or one stay Societal cost — one illness Economy-wide loss Derivation and inputs
COVID-19 $11,275 mean hospital cost per inpatient stay [2020–22]; $13,072 by March 2022; $36,484 when ECMO was used [1] — (no clean case denominator; see below) ≈ $42,200 per US resident: $14 trillion ÷ 331.4 million [through 2023] [2][3] Medical: adjusted mean of 1,333,404 stays at 841 hospitals, hospitals' cost to provide care, not charges. Economy-wide: USC Schaeffer Center's model estimate of cumulative GDP below the no-pandemic path, divided by the 2020 Census count — a projection, not a measurement, as the COVID economic impact page explains.
Norovirus When care is sought: median $640 outpatient, $2,203 emergency department, $14,083 inpatient [2024] [4] $505 – $558 [2020]: $10.6 billion ÷ 21 million; ÷ 19 million [5][6]. Foodborne case: $543 [2023] [7] $10.6 billion a year, US; 89% of it lost productivity [5] Societal: Bartsch 2020's annual burden ÷ CDC's 19–21 million illnesses, as on the norovirus economic impact page. ERS figure: $2,968,300,000 ÷ 5,461,731 foodborne cases. Medical: Veterans Health Administration medians, laboratory-confirmed episodes, median age 62 — an upper bound for community cases, most of which see no clinician. Per outbreak: median 22 illnesses × $505–$558 ≈ $11,100–$12,300, worked through on the outbreak cost page.
Ebola ≈ $580,000 per US patient [2014]: $1.16 million ÷ 2 patients, about $30,000 a day for ~18 days [8][9]; ≈ $823,000 in August 2026 dollars (CPI-U 236.151 → 334.98) [10] — ≈ $1.86 million per reported case, West Africa 2014–16: $53.19 billion ÷ 28,610 cases [11] Medical: the Nebraska Medical Center's sworn testimony to a House subcommittee, the only on-the-record per-patient figure; Emory put its cost for one high-intensity patient at "close to $1 million" [9]. Full derivation on the Ebola treatment cost page. Economy-wide: Huber et al.'s comprehensive economic and social burden ÷ CDC's case count, as on the Ebola economic impact page; $18.8 billion of the numerator is deaths from non-Ebola causes.
Hantavirus (HPS) No hantavirus-specific figure. Inputs for a severe case: an ECMO course $42,554 – $537,554 [2013] [12]; mechanical ventilation adds $1,522 per day [2002] [13]; mean HPS stay on ECMO 20.8 days [14] — — (no aggregate estimate exists; ~30 cases a year is too few for cost-of-illness methods) Deliberately not multiplied out. The hantavirus economic impact page explains why: thirty cases a year times a per-case cost spanning an order of magnitude yields a number with an implied precision its inputs cannot support. At the ECMO review's midpoint (~$290,000) one severe case costs more than 3,000 DIY cleanup kits.
Seasonal influenza Direct medical: $3.2 billion a year ÷ ≈ 26.2 million illnesses ≈ $122 per illness [2015] [15] ≈ $427 per illness [2015]: $11.2 billion ÷ ≈ 26.2 million [15] $11.2 billion a year, US ($6.3–$25.3 billion); $8.0 billion of it lost productivity [15] Putri et al.'s average annual burden, 2015 population. The denominator is our sum of the study's four outcome counts — 21.6 million ill but not medically attended, 3.7 million outpatient visits, 0.65 million emergency visits and 247,000 hospitalizations — treated as ≈ 26.2 million illness episodes; a person can appear in more than one category, so the per-illness figures are slightly low.
Measles Public-health response: median $32,805 per case (range $7,396–$76,154); median $152,308 per outbreak; $223 per contact traced [16] — — CDC authors' review of 10 studies covering 11 US outbreaks, 2004–2017. The cost is the health department's — case investigation, contact tracing, post-exposure prophylaxis, quarantine — and is the per-case price of a disease the country eliminated in 2000 and keeps re-importing. Medical care of the patient is not included in most of the studies.
West Nile virus Initial hospital and lost-productivity cost, by syndrome, medians [2003]: acute flaccid paralysis $25,117; encephalitis $20,105. Long-term (5 years): AFP $22,628; meningitis $10,556 [17] — $778 million cumulative for reported hospitalized cases, 1999–2012 (95% CI $673 million–$1.01 billion) [17] CDC authors, 80 Colorado patients hospitalized in 2003, 38 followed for five years; the national figure is their extrapolation to surveillance counts. Ranges are enormous — up to $324,167 initial and $439,945 long-term for single patients.

What the Table Shows

  1. Per case and in total are opposite rankings. Norovirus and influenza are the cheapest illnesses in the table at $400–$560 each, and the most expensive in total — $10.6 billion and $11.2 billion a year — because they infect tens of millions of people. Ebola is the most expensive per patient and, in the United States, cost about $6.4 million to treat in total (11 patients × ~$580,000 [8][9]) — a rounding error beside the $361 million US acute-care hospitals spent preparing for patients that never came [18]. For a rare, severe virus the cost is readiness; for a common, mild one it is volume.
  2. The most expensive routine case is a preventable one. At a median $32,805 per case in public-health response alone, a measles case costs the health department more than a COVID-19 hospitalization costs the hospital (~$11,275) — for a disease with a vaccine. The per-contact figure, $223, times the hundreds of contacts a single case in a clinic or airport generates, is where the money goes.
  3. A hospitalization is not the expensive part of most viruses. Norovirus's societal cost per illness ($505–$558) is nearly all lost work; its medical column only matters for the roughly 2% of outbreak cases who are admitted. Influenza's direct medical cost is $122 of a $427 illness. The exceptions are the viruses that put nearly everyone in hospital — Ebola, severe hantavirus, West Nile neuroinvasive disease — where the medical column is the cost.
  4. The economy-wide column is a different subject. Ebola's $1.86 million per West African case and COVID-19's $42,200 per American are not what anyone paid for treatment; they are the price of fear and disruption, distributed over whole populations. Both economic-impact pages call this "aversion", and it is why the network's cross-disease economic overview sorts viruses by mechanism rather than by size.

What Is Deliberately Blank

The Risk Perspective's rule is that a figure that does not exist is marked as not existing — never estimated, interpolated or carried over from a different population. The same rule governs this page. The blanks, and why:

  • COVID-19, cost per case. COVID-19 is no longer nationally notifiable and reported cases never approximated infections, so every "cost per case" would be a total divided by a number nobody believes. The Risk Perspective leaves its case-rate cell blank for the same reason; this page follows it.
  • Hantavirus, any aggregate. Published inputs exist; multiplying them by thirty cases a year would manufacture precision. The inputs are shown instead.
  • Eight viruses with no row — RSV, dengue, Zika, mpox, rabies, Powassan, Marburg and H5N1 avian influenza. Each has cost literature; none was verified for this first version against the sourcing rule, and a row assembled from a press release or a single small study would be worse than none. They are the next additions, in that order of case volume, and will be added when a Tier 1, 1.5 or 2 per-case figure has been read in full.

How a Figure Earns Its Place Here

The hub's data guard machine-checks the fifteen Risk Perspective records for source tier, derivation inputs and geography; this page is prose, so that guard does not read it, and its figures are held to the same standard by hand instead. Each figure comes from CDC, WHO or NIH directly (Tier 1), an official statistics body such as the Bureau of Labor Statistics, the Census Bureau or USDA's Economic Research Service (Tier 1.5), a congressional record, or peer-reviewed literature cited by DOI (Tier 2). No aggregators, media estimates or vendor figures are used, and every derived cell names both its numerator and its denominator. The full scheme is on Our Sources.

Frequently Asked Questions

Which virus costs the most per case?

In direct medical cost of one US patient, Ebola (~$580,000 in 2014; ~$823,000 today). In public-health response per case, measles (median $32,805). In economy-wide cost per case, Ebola in West Africa (~$1.86 million, mostly borne by the uninfected). Per case, norovirus and influenza are cheapest at $400–$560 — and dearest in total.

How much does a COVID-19 hospitalization cost?

An adjusted mean of $11,275 per stay across 1.33 million stays in 2020–22, rising to $13,072 by March 2022; $36,484 where ECMO was used (Kapinos et al., JAMA Netw Open 2024). That is the hospital's cost to provide care, not what was billed.

Why is there no cost per COVID-19 case?

No clean denominator exists — COVID-19 is not nationally notifiable and reported cases never captured infections. The table gives cost per hospital stay, which has a real denominator, and USC Schaeffer's $14 trillion model estimate per US resident (~$42,200), which needs no case count.

Can the columns be added?

No. Medical cost is one input to societal cost, and economy-wide loss is a different quantity again — output that never happened, mostly in people who were never ill. They are three answers to the question, not three parts of one.

This page compiles published economic estimates for comparison. It is not medical advice or a risk assessment for any individual; the health figures behind these costs, with their own sources, are on the Virus Risk Perspective.

Sources & References

  1. Kapinos KA, Peters RM Jr, Murphy RE, et al. Inpatient costs of treating patients with COVID-19. JAMA Netw Open 2024;7(1):e2350145 — adjusted mean $11,275 (95% CI $11,252–$11,297); $10,394 (March 2020) to $13,072 (March 2022); ECMO stays $36,484. doi:10.1001/jamanetworkopen.2023.50145
  2. Hlávka JP, Rose A, et al. COVID-19's total cost to the U.S. economy will reach $14 trillion by end of 2023. USC Schaeffer Center, May 2023 — a computable general-equilibrium model estimate. schaeffer.usc.edu
  3. U.S. Census Bureau. 2020 Census apportionment population: 331,449,281. census.gov
  4. Cates JE, Nelson RE, Suo Y, et al. Health care costs associated with norovirus at the Veterans Health Administration. JAMA Netw Open 2025;8(10):e2536600 — medians $640 / $2,203 / $14,083 (2024 dollars). doi:10.1001/jamanetworkopen.2025.36600
  5. Bartsch SM, O'Shea KJ, Lee BY. The clinical and economic burden of norovirus gastroenteritis in the United States. J Infect Dis 2020;222(11):1910–9 — $10.6 billion a year; ~89% productivity losses. doi:10.1093/infdis/jiaa292
  6. Centers for Disease Control and Prevention. Norovirus facts and stats — 19–21 million illnesses a year, as cited on the norovirus economic impact page. cdc.gov/norovirus/data-research
  7. U.S. Department of Agriculture, Economic Research Service. Cost estimates of foodborne illnesses, 2025 update (2023 dollars) — norovirus 5,461,731 cases, $2,968,300,000, $543 per case. ers.usda.gov
  8. Gold JB. Statement of Chancellor Jeff Gold, M.D., University of Nebraska Medical Center, and hearing transcript, House Committee on Energy and Commerce, Subcommittee on Oversight & Investigations, November 18, 2014 — "$1.16 million to treat the two patients"; "approximately $30,000 per day"; stays of 18 days. docs.house.gov (PDF)
  9. Lo Piccolo AJ, McGuire E, Postelnicu R, et al. From Ebola to H5N1: strengthening the U.S. special pathogen response system. Epidemiologia 2026;7(3):79 — Emory's "close to $1 million" per high-intensity patient; Herstein JJ et al. Emerg Infect Dis 2016;22(2):350–2 for the count of 11 US patients (doi:10.3201/eid2202.151431). doi:10.3390/epidemiologia7030079
  10. U.S. Bureau of Labor Statistics. CPI-U, all items, US city average, NSA (CUUR0000SA0) — November 2014 236.151; August 2026 334.98. data.bls.gov
  11. Huber C, Finelli L, Stevens W. The economic and social burden of the 2014 Ebola outbreak in West Africa. J Infect Dis 2018;218(suppl 5):S698–S704 — $53.19 billion (2014 dollars); CDC, History of Ebola outbreaks, 28,610 cases. doi:10.1093/infdis/jiy213
  12. Harvey MJ, Gaies MG, Prosser LA. U.S. and international in-hospital costs of extracorporeal membrane oxygenation: a systematic review. Appl Health Econ Health Policy 2015;13(4):341–57 — $42,554–$537,554 (2013 values), 18 studies. PubMed 25894740
  13. Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med 2005;33(6):1266–71 — incremental $1,522 per ventilated day (2002 dollars). doi:10.1097/01.ccm.0000164543.14619.00
  14. Dietl CA, Wernly JA, Pett SB, et al. Extracorporeal membrane oxygenation support improves survival of patients with severe hantavirus cardiopulmonary syndrome. J Thorac Cardiovasc Surg 2008;135(3):579–84 — mean stay 20.8 days (range 10–39), as cited on the hantavirus cleanup cost page. PubMed 18329474
  15. Putri WCWS, Muscatello DJ, Stockwell MS, Newall AT. Economic burden of seasonal influenza in the United States. Vaccine 2018;36(27):3960–6 — $11.2 billion ($6.3–$25.3 billion); direct $3.2 billion; indirect $8.0 billion; 21.6 million non-attended illnesses, 3.7 million outpatient visits, 0.65 million ED visits, 247,000 hospitalizations, 36,300 deaths. doi:10.1016/j.vaccine.2018.05.057
  16. Pike J, Leidner AJ, Gastañaduy PA. A review of measles outbreak cost estimates from the United States in the postelimination era (2004–2017): estimates by perspective and cost type. Clin Infect Dis 2020;71(6):1568–76 — median $152,308 per outbreak (range $9,862–$1,063,936); $32,805 per case ($7,396–$76,154); $223 per contact ($81–$746). doi:10.1093/cid/ciaa070
  17. Staples JE, Shankar MB, Sejvar JJ, Meltzer MI, Fischer M. Initial and long-term costs of patients hospitalized with West Nile virus disease. Am J Trop Med Hyg 2014;90(3):402–9 — medians and ranges as tabulated; $778 million cumulative 1999–2012. doi:10.4269/ajtmh.13-0206
  18. Smit MA, Rasinski KA, Braun BI, et al. Ebola preparedness resources for acute-care hospitals in the United States. Infect Control Hosp Epidemiol 2017;38(4):405–10 — $361,108,968 national preparedness cost. doi:10.1017/ice.2017.6

The pages this table is built from: what it cost to treat Ebola in the US · what a norovirus outbreak costs · COVID-19 economic impact · hantavirus economic burden · the cross-disease economic overview · the Virus Risk Perspective